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Previously, we showed that serum resistance in Haemophilus ducreyi type strain 35000HP required expression
of the outer membrane protein DsrA because the isogenic dsrA mutant FX517 is highly serum susceptible. In
this study, we confirmed this finding by construction of additional serum-susceptible dsrA mutants in more
recently isolated serum-resistant strains. We also demonstrated that killing of dsrA mutants required an intact
classical complement cascade but not the alternative or mannan-binding lectin pathways. Between 5- and
10-fold more purified human immunoglobulin M (IgM) but not IgG was deposited onto dsrA mutant FX517
than onto parent strain 35000HP, consistent with IgM initiation of the classical cascade. Depletion of IgM, but
not IgG, from complement-intact serum inhibited killing of FX517. As predicted from the amounts of IgM
bound, more of the individual complement components were bound by FX517 than by parent strain 35000HP.
Examination of the binding of negative regulators of complement as an explanation for serum resistance
indicated that parent strain 35000HP bound more C4 binding protein and vitronectin than FX517 but not
factor H. However, the degree and pattern of complement component binding observed suggested that IgM
binding to the serum-susceptible mutant FX517 was responsible for the activation of the classical pathway and
the observed killing of FX517 as opposed to binding of negative regulators of complement by the serum-
resistant parent. We speculate that an undefined neo-epitope, possibly carbohydrate, is exposed in the dsrA
mutant that is recognized by naturally occurring bactericidal IgM antibodies present in human sera.
Haemophilus ducreyi is the etiologic agent of chancroid, one
of the sexually transmitted genital ulcer diseases. H. ducreyi is
a fastidious gram-negative bacterium noted for its obligate
requirement for heme and is a strict human pathogen. Chan-
croid is prevalent in many developing countries, including cer-
tain parts of Africa, Asia, and South America (28). There has
been a renewed interest in chancroid because it has been
shown to be an independent risk factor for the transmission of
human immunodeficiency virus (32). Elimination of chancroid
is feasible for commercial sex workers and results in a signifi-
cant decrease of chancroid in their male clients (37a). Elimi-
nation of chancroid could potentially slow human immunode-
ficiency virus transmission in Africa.
H. ducreyi is highly resistant to killing by fresh normal human
serum (fNHS) (commonly termed “serum resistance”) (31).
Serum resistance has been demonstrated to be a critical factor
for survival and establishment of disease in many bacterial
systems (25). Microbes utilize multiple strategies to resist kill-
ing by fNHS. A common mechanism of serum resistance uses
surface-exposed bacterial proteins to bind negative regulators
of complement (C). For example, certain Neisseria gonor-
rhoeae porins (33), Bordetella pertussis filamentous hemagglu-
tinin (5), and Streptococcus pyogenes M proteins (6) bind C4
binding protein (C4bp). Borrelia burgdorferi OspE (18), Neis-
seria gonorrhoeae Por1A (35), and Streptococcus pneumoniae
PspC (12) bind factor H (fH). It is not known what mechanism
H. ducreyi uses to resist killing by fNHS.
Early studies on serum resistance in H. ducreyi by Odumeru
and colleagues in the mid-1980s showed that virulent strains
were resistant to fresh normal human or rabbit serum while
avirulent strains were serum susceptible (31). In Odumeru’s
studies, serum-susceptible strains contained truncated lipo-
oligosaccharide (LOS) and were nonisogenic to the serum-
resistant strains; Odumeru concluded that truncated LOS was
responsible for the serum-susceptible phenotype (29–31). How-
ever, two more recent studies using isogenic mutants con-
cluded that LOS (15, 19) is not a major determinant of serum
resistance in H. ducreyi. LOS isogenic mutants of type strain
35000HP are not serum susceptible (19) and are fully virulent
in the human model of chancroid infection (44, 45). In con-
trast, isogenic or naturally occurring mutants in the gene en-
coding the outer membrane protein DsrA are 10- to 100-fold
more serum sensitive than virulent parent strain 35000HP. The
isogenic dsrA mutant FX517 was attenuated in the human
model of chancroid infection (7), emphasizing the importance
of DsrA. Very recently, we have identified a second novel
outer membrane protein also required for expression of full
serum resistance in H. ducreyi (22). dltA mutants are moderate-
ly serum susceptible, and dltA/dsrA double mutants are the most
serum susceptible of any H. ducreyi strain reported to date.
Odumeru’s studies also examined the role of the classical
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and alternative pathways in serum resistance and concluded
that killing of serum-susceptible H. ducreyi was due to the
classical pathway, since EGTA inhibited killing. However, this
result, observed prior to the recognition of the importance of
the mannose binding lectin (MBL) pathway, would also be
consistent with activation by the MBL pathway. Furthermore,
results from studies on serum resistance and H. ducreyi con-
ducted by Lagergard et al. (21) suggested that in addition to
the classical pathway, the alternative pathway might also be
important in the killing of H. ducreyi.
The objective of this study was to confirm and extend our
earlier finding that DsrA expression is required for serum
resistance by using more recently isolated and geographically
distinct H. ducreyi strains and their isogenic dsrA mutants.
Furthermore, we sought to clarify the relative roles of the
classical, MBL, and alternative complement pathways in the
killing of serum-susceptible H. ducreyi. Finally, we sought to
identify where in the complement cascade activation occurred.
MATERIALS AND METHODS
Strains and media. The H. ducreyi strains used in this study are shown in Table
1. The extensively characterized type strain 35000HP and two recent isolates,
010-2 and 425 (13), and their corresponding dsrA mutants, FX517 (15), FX529,
and FX530, were grown on chocolate agar plates (GC medium base, 1% hemo-
globin, 1% GGC) supplemented with 5% fetal calf serum (FCS). Optimal growth
and a more consistent expression of the serum-resistant phenotype was obtained
when strains were grown on chocolate agar containing 5% FCS than in previous
studies where FCS was not used (data not shown). Strains were maintained at
35°C with 5% CO2.
Construction of dsrA mutants in recent isolates. dsrA mutants for parent
strains 010-2 and 425 were constructed as previously described for strain
35000HP (15). The mutagenesis plasmid pUNCH 1256 (15) was used to elec-
troporate 010-02 and 425 to form FX529 and FX530, respectively. Strains were
confirmed by PCR using dsrA primers 14 and 24 (15). PCR of mutants yielded a
band approximately 1 kb larger than that of the parent, consistent with the
insertion of a 1-kb chloramphenicol cassette in the dsrA gene. Western blotting
using antiserum to recombinant DsrA (9) revealed that each mutant lacked
expression of DsrA.
Complementation of dsrA mutants FX529 and FX530. The dsrA mutants
FX529 and FX530 were complemented as previously described by Elkins et al.
(15). Briefly, plasmid pUNCH 1260 dsrA (strain 35000HP) or the empty vector
pLSKS (negative control) were electroporated into dsrA mutants FX529 and
FX530. Strains containing pUNCH 1260 or pLSKS were grown on chocolate
agar containing streptomycin at 100 g/ml. Expression of dsrA in complemented
mutants was confirmed by Western blotting. Bactericidal assays were performed
using the complemented mutants as described below.
Bactericidal assay. Bactericidal assays were performed as previously described
(15). Chocolate agar cultures of H. ducreyi, 16 to 18 h old, were used to prepare
bacterial suspensions for each strain at an optical density at 600 nm (OD600) of
0.2 (approximately 1  108 CFU/ml) in gonococcal medium base broth (GCB)
(Difco). Fifty microliters of a 105 dilution of H. ducreyi was mixed with 50 l of
either pooled fNHS or heat-inactivated NHS (hNHS) to achieve a final concen-
tration of 50% serum. Normal human serum was prepared from blood collected
from four volunteers. In experiments using various percentages of sera, volumes
of bacteria and serum were adjusted appropriately to the desired concentration
of serum. Following incubation for 45 min at 35°C in the presence of 5% CO2,
aliquots were plated onto chocolate agar plates and incubated for 48 h, and
viable colonies were counted. Data are expressed as percent survival in fNHS
compared to that in hNHS [(CFU in fNHS/CFU in hNHS)  100].
Inhibition of classical and MBL pathways. Activation of the complement
system proceeds by three pathways, the classical pathway, the MBL pathway, and
the alternative pathway (41). To determine which pathway is responsible for
killing in H. ducreyi, we used EGTA to chelate the calcium ions in NHS. The
classical pathway and the MBL pathway are both calcium-dependent pathways
and are therefore inactive in calcium-depleted serum (11, 26, 38, 39). The
alternative pathway requires magnesium for its activity and is not affected by the
absence of calcium. However, because EGTA also binds magnesium, albeit at a
lower affinity, we supplemented the chelated serum with 2 mM MgCl2 (16). Fifty
microliters of NHS, chelated with 20 mM EGTA plus 2 mM MgCl2 (fNHS-
EGTA/MgCl2), was added to 50-l aliquots of H. ducreyi, and the bactericidal
assay was performed as described above.
Specific inhibition of classical pathway. In order to differentiate between the
role of the classical pathway and that of the MBL pathway in killing of H. ducreyi,
we used C1q-depleted serum (Advanced Research Technologies [ART]). Re-
moval of C1q from normal human serum specifically inhibits the classical path-
way but not the MBL pathway (26). Fifty-microliter aliquots of H. ducreyi sus-
pensions were incubated with either 50 l of fNHS, C1q-depleted fNHS (fNHS/
C1q), or C1q-depleted serum reconstituted with 100 g/ml of purified C1q
(fNHS/C1q/C1q), and the bactericidal assay was performed as previously
described. The process used to deplete the serum of C1q also chelates the
calcium and magnesium ions (William Kolb, ART, personal communication).
Therefore, we supplemented our C1q-depleted serum with 5 mM CaCl2 and 2
mM MgCl2 to restore classical pathway activity. The level of MBL in the Clq-
depleted serum was examined by Western blotting and found to be comparable
to that of NHS (data not shown).
Statistical analysis. Comparison of serum-resistant parents and serum-suscep-
tible dsrA mutants was performed using a standardized t test for multiple com-
parisons. A P value of 0.05 was accepted as the level of statistical significance.
Immunoglobulin binding to H. ducreyi. Two hundred micrograms of purified
human immunoglobulin M (IgM) (Sigma I-8260, lots 115H48011 and 087H4832)
or IgG (purified from NHS using protein G agarose [Sigma]) was iodinated as
previously described (15). Fifty microliters of H. ducreyi 35000HP, FX517 (OD 
0.4, approximately 2  108 CFU), or no bacteria suspended in GCB was mixed
with 125I-IgM or IgG (2.5  106 cpm) in a multiscreen plate (Multiscreen-HV,
catalog no. MAHVN4550; Millipore, Inc). Plates were incubated at 34°C in 5%
CO2 for 45 min. Plates were suctioned and washed five times with phosphate-
buffered saline (PBS), and H. ducreyi-associated cpm were determined by gamma
counting. Net cpm bound to 35000HP or FX517 were determined by subtracting
cpm present in wells that received no H. ducreyi.
Western blot assays for the measurement of complement components. Com-
plement protein deposition onto H. ducreyi was measured following incubation
with NHS. Bound complement components were measured by Western blotting
using specific antisera or monoclonal antibodies (MAbs) to various complement
proteins. H. ducreyi suspensions were prepared in GCB to an OD of 0.5 at 600
nm using a 16- to 18-h culture of 35000HP or FX517. Bacterial suspensions (500
l) were mixed with indicated volumes of either fNHS or hNHS to achieve the
desired percentage of NHS and incubated for 45 min. For time course studies,
samples were incubated for 1, 10, 30, or 45 min. To verify that bands observed in
Western blots were not due to antibody binding to H. ducreyi proteins, bacterial
suspensions were incubated in the absence of NHS. Following incubation, cells
were placed on ice for 5 min, centrifuged for 2 min, and washed three times with
cold GCB. After the final wash, cell pellets were resuspended in 100 l of
Laemmli sample buffer. Twenty-microliter samples were electrophoresed on a
sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel and electrotransferred
to a nitrocellulose membrane. Samples for C4bp, C6, and C7 detection were
prepared under nonreducing conditions, because under reducing conditions no
signal was obtained. All other gels were run under reducing conditions. Mem-
TABLE 1. Bacterial strains and plasmids






35000HP Wild type, parent 37
FX517 35000HP dsrA, Cmr 15
425 Wild type, parent 13; Mississippi
FX529 425 dsrA, Cmr This work
010-2 Wild type, parent 13; Dominican
Republic
FX530 010-2 dsrA, Cmr This work
E. coli DH5 recA gryB Invitrogen
Plasmids
pUNCH 1256 Mutagenized dsrA in pRSM1791 15
pUNCH 1260 dsrA PCR clone in pLSKS 15
pLSKS Shuttle plasmid, Strr 43
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branes were blocked with 2% bovine serum albumin in 1 PBS containing 0.1%
azide (blocker) for 1 h. Membranes were then probed with the following com-
plement antibodies: C7 and C6 (ART) and C4bp (Quidel) at a 1:5,000 dilution;
C3 and C4 (ART) at a 1:1,000 dilution in blocker. The secondary antibodies used
were anti-mouse or anti-goat alkaline phosphatase (Sigma) as appropriate at a
1:5,000 dilution. Bound antibody was detected using a chemiluminescent sub-
strate (Lumi-Phos; Pierce).
Well-characterized Neisseria gonorrhoeae strains FA6564 (Por1A) and F62
were used as controls to test for the ability of our Western blot assay to discrim-
inate between differences in complement protein deposition (34). FA6564 is
resistant to killing in 10% NHS, whereas F62 is susceptible. Gonococcal strains
were incubated with NHS as described above, using a final serum concentration
of 10%. Western blot analysis of complement binding to these strains was carried
out as described for H. ducreyi strains.
C9 deposition. C9 deposition was determined using 125I-labeled anti-SC5b-9
monoclonal antibody (Quidel, catalog no. A239). One hundred micrograms of
antibody was iodinated as previously described (14). H. ducreyi cell suspensions
were prepared to an OD600 of 0.5 in GCB medium, and 100 l of this suspension
was mixed with 100 l of either GCB, hNHS, or fNHS in a 96-well multiscreen
plate. Following incubation with NHS, cells were suctioned onto the filter mem-
brane and washed four times with 1 PBS. Approximately 1  106 cpm of
iodinated anti-SC5b-9 was added to each well, and binding was allowed to
proceed for 30 min at room temperature. Cells were again washed four times
with 1 PBS-Ca-Mg, and filters containing the bacteria and bound proteins were
allowed to dry. Dried filters were punched out into 12- by 75-mm glass tubes, and
H. ducreyi-associated cpm were determined using a gamma counter.
C4BP binding to H. ducreyi. Purified C4BP (generously provided by Anna Blom,
University of Lund, Malmo, Sweden) binding was performed as described above for
purified immunoglobulin binding, except that iodinated C4BP was used. Iodinated
C4BP (approximately 1  106 cpm) was mixed with H. ducreyi or gonococcal
controls (approximately 1  107 CFU in a total volume of 100 l) for 45 min. After
washing bacteria, bound C4BP was determined by gamma counting.
C-reactive protein (CRP) and phosphorylcholine (PC) experiments. Immobi-
lized PC (Pierce Chemicals) was used to deplete CRP from NHS using PC
agarose (Pierce Chemicals) (42). Greater than 95% of CRP was depleted as
assayed by Western blotting using anti-CRP (data not shown). As an additional
control, Haemophilus influenzae strains expressing (strain 418) or not expressing
(strain 419) PC on their LOS were used as controls (17). Bactericidals of H.
influenzae utilized 10% NHS, whereas bactericidals of FX517 utilized 20% se-
rum. We also examined whether H. ducreyi expressed PC on its LOS by Western
blots using the anti-PC MAb TEPC-15 and used H. influenzae strains 418 and 419
as positive and negative controls, respectively (42). Crude LOS was prepared by
using proteinase K as described by Hitchcock and Brown (20).
Depletion of immunoglobulins. IgG was depleted from fresh NHS by using
recombinant protein G agarose (no 1197; capacity, 20 mg/ml human IgG of
packed gel; exalpha). IgM was depleted using anti-human IgM agarose (no.
A-9935; capacity, 2.4 mg/ml packed gel; Sigma). Briefly, an excess of prechilled
immunosorbent (2 ml packed) equilibrated in cold PBS was mixed with chilled
fNHS (3 ml, pooled or individual sera) and gently rocked for 15 min on ice. The
agarose was centrifuged, and the serum supernatant was filter sterilized. This
process diluted NHS approximately by 1/3 based on total protein determinations
due to residual PBS in packed agarose. Control agarose lacking bound ligands
was used to control for nonspecific binding of serum components and serum
dilution. The depleted sera were tested for bactericidal activity against strain
FX517 as described above. Depletion of IgG and IgM was confirmed at the UNC
Hospitals Clinical Immunology Laboratories and in Western blots in our labo-
ratory using antisera specific to each class. Greater than 90% of IgG or IgM was
removed by the adsorption techniques described above.
To confirm that depletion of IgM inhibited killing of FX517, we reconstituted
depleted serum with purified IgM (I-8260; Sigma). IgM-depleted serum when
reconstituted with purified IgM brought IgM levels to normal serum levels. To
ensure that depletion of IgM had no effect on IgG levels or activity, we used an
additional control in which we added IgG (I-4506; Sigma; or eluted from the
protein G column above) to IgM-depleted sera. IgM-depleted serum reconsti-
tuted with purified IgG resulted in levels of IgG that were approximately twice
that of NHS. The intact complement activity was also measured by the addition
of heat-inactivated serum (as the source of immunoglobulins) to IgM-depleted
sera. The reconstituted sera were used in bactericidal assays with FX517.
Absorption of fNHS with FX517 to remove bactericidal antibodies. Strain
FX517 was suspended in GCB medium to an OD600 of 1.0. This suspension was
chilled, 1 ml was centrifuged, and the pellet was resuspended in 0.4 ml fNHS.
After incubation for 1 h, the suspension was centrifuged and the supernatant
absorbed twice more but for 30 min each. After the last absorption, the serum
was filter sterilized (0.45 m) and used for bactericidal assays as described above
at 25%. Absorbed serum bactericidal activity was reconstituted with purified IgM
as described in the preceding section or with 25% hNHS (as a source of immu-
noglobulins).
RESULTS
Further evidence that expression of dsrA is required for
serum resistance in H. ducreyi. Previous work from our labo-
ratory showed that DsrA is required for high-level serum re-
sistance in H. ducreyi strain 35000HP and in certain other
strains isolated in the distant past (15). To confirm the impor-
tance of DsrA in serum resistance, we constructed isogenic dsrA
mutants in more recently isolated strains. Strains 010-2 and 425
were chosen for dsrA mutagenesis based on the following criteria:
high levels of serum resistance, geographic distinction, and lack of
plasmids and chloramphenicol sensitivity. dsrA mutants FX529
(parent strain 010-2) and FX530 (parent strain 425) were con-
firmed by PCR and Western blotting as described in Materials
and Methods. In contrast to parent strains 010-2 and 425, which
exhibited high levels of serum resistance, FX529 and FX530 were
more serum susceptible, exhibiting only 1% and 0.1% survival
(Fig. 1). Complementation of FX529 and FX530 with a plasmid
expressing DsrA from strain 35000HP (pUNCH 1260) restored
the serum-resistant phenotype (data not shown). These results
confirm our earlier findings and provide further evidence for the
essential role of DsrA in serum resistance.
The classical pathway is required for complement-mediated
killing of H. ducreyi mutant FX517. Activation of complement
generally requires antibody binding (classical pathway), man-
nan binding lectin binding to carbohydrate structures on mi-
crobes (MBL pathway), or direct C3b binding to microbial
surfaces (alternative pathway) (41). EGTA, in the presence of
Mg2 (EGTA/Mg), inhibits both the classical and the mannose
binding lectin pathway but not the alternative pathway in
bactericidal killing assays (26). Treatment of serum with
EGTA/Mg prevented killing of serum-susceptible dsrA mu-
tants FX517 and FX529 (88% and 100% survival, respectively
[Fig. 2]) as contrasted to nonchelated serum (0.1 and 0.8 per-
cent in fNHS for FX517 and FX529, respectively). To distin-
guish between the classical and MBL pathways, we conducted
FIG. 1. Bactericidal killing of H. ducreyi parent strains and dsrA
mutants. The indicated parent strains and their isogenic dsrA mutants
were incubated with NHS for 45 min, and numbers of CFU were
determined by plating. Percent survival was calculated by dividing the
CFU from fNHS by CFU from hNHS and multiplying by 100. The P
values for strains 35000HP (35000), 010-2, and 425 and each of their
isogenic mutants were 0.0001, 0.0001, and 0.0001, respectively.
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bactericidal experiments using C1q-depleted serum, a C com-
ponent required for the classical pathway but not required for
the MBL pathway. The survival rates for the serum-susceptible
dsrA mutants FX517 and FX529 in fNHS were 1.2% and 1%,
respectively (Fig. 3). When FX517 and FX529 were incubated
with C1q-depleted NHS, the survival rate increased to 93%
and 88% survival, respectively. The addition of purified C1q to
the C1q-depleted serum partially restored serum killing (21%
and 20% survival for FX517 and FX529, respectively). We did
not fully reconstitute killing. However, in erythrocyte lysis as-
says (50% hemolytic complement assay) used to determine the
efficiency of reconstituted C1q serum, the complement activity
is at least 80% of that in normal serum (personal communica-
tion; Kolb). This 50% hemolytic complement value is compa-
rable to the level of bacterial killing observed in our study. To
further examine the possible role of MBL activation of com-
plement, we measured MBL binding. Less than 0.5 nanograms
of MBL bound to the surfaces of 35000HP and FX517 (data
not shown). These data suggest that the classical but not the
mannan binding lectin or alternative pathway is essential for
killing of dsrA mutants FX517 and FX529.
Immunoglobulin binding to H. ducreyi. Generally, activation
of the classical pathway is achieved through antibody binding,
although in certain systems, spontaneous binding of C com-
ponents in the absence of antibody occurs, leading to bacterial
death (1, 2, 42). To measure immunoglobulin-mediated initi-
ation of the classical pathway, iodinated purified human IgM
or IgG was mixed separately with suspensions of H. ducreyi
35000HP and FX517. After incubation and washing, the
amount of bound immunoglobulin was determined by gamma
counting. H. ducreyi FX517 bound approximately 5- to 10-fold
more IgM than parent strain 35000HP, depending on the lot of
IgM used (Fig. 4). The difference in IgG binding to 35000HP
and FX17 was not as great as that observed for IgM binding
and did not reach statistical significance.
C1q binding. C1q, the first C component, was studied using
a time course experiment. Using fNHS as the source of C1q,
C1q was deposited as early as 1 min on FX517 (Fig. 5). Inter-
estingly, the amount of C1q deposited in fNHS increased and
then decreased over time. Clq deposition was not observed in
35000HP samples incubated in fNHS. In hNHS, where C1q is
denatured and inactive (26), C1q binding was observed only in
samples incubated for 45 min with hNHS. Using purified C1q
or C1qrs holocomplex in the absence of antibody, more C1q
was deposited at 45 min on FX517 than on 35000HP (data not
shown). Taken together, C1q binding in heated NHS at later
time points and purified C1q binding may represent nonfunc-
tional binding, since this binding neither correlated temporally
with the binding of C1q nor with the killing of bacteria in fNHS
(data not shown).
C4 and C3 binding. C4 and C3, the components immediately
following C1, were measured using the Western blot assay.
Functional C4 and C3 alpha chains, but not beta chains, form
covalent ester and amide bonds with certain acceptor mole-
cules on the membranes of bacteria that are not broken by the
conditions used for SDS-PAGE in this study (26). Since the
various acceptor molecules vary in molecular mass, the alpha
chain complexes often form a heterogeneous smear of co-
valently bound reactive material in the fNHS lanes. The beta
chains released from these complexes migrate independently
of the alpha chains and acceptor molecules. For all forms of C4
and C3, more was deposited on FX517 than on 35000HP (Fig.
FIG. 2. NHS killing of dsrA mutants requires Ca2. The indicated
dsrA mutants were subjected to bactericidal killing in the presence and
absence of EGTA/Mg. P values for FX517 and FX529 (fNHS versus
fNHS plus EGTA/Mg) were 0.0001 for both strains.
FIG. 3. Bactericidal killing of dsrA mutants requires Clq. Bactericidal
killing (50% NHS) was performed as described using NHS (fNHS), NHS
depleted of C1q (fNHS/C1q), or NHS depleted of C1q and then recon-
stituted with physiological concentrations of purified C1q (fNHS/C1q/
C1q). P values for FX517 and FX529 (fNHS versus fNHS/C1q) were
 0.0001 and  0.0001, respectively. P values for both strains (fNHS/
C1q versus. fNHS/C1q/C1q) were 0.0001.
FIG. 4. Binding of immunoglobulins by H. ducreyi. The indicated
strains of H. ducreyi (1  107 CFU) were mixed with iodinated purified
human IgM or IgG (1  106 cpm) in a total volume of 100 l. After 45
min, the H. ducreyi strains were suctioned and washed five times with
PBS, and bacteria-associated radioactivity was determined. P values
for 35000HP (35000) versus FX517 for IgM depletion and IgG deple-
tion were 0.0001 and 0.0693, respectively.
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6, right panel). Specifically, high-molecular-weight smears of
immunoreactive material representing C4 and C3 alpha chains
covalently bound to acceptor molecules were observed in fresh
but not heated NHS. Similarly, there was an increase in non-
covalently bound beta chains in FX517 incubated in fNHS
compared to results with hNHS. Noncovalent binding of C3
was observed in hNHS samples and migrated at a position in
the gel consistent with the reduced forms of C3 alpha chain
(115 kDa) and beta chain (75 kDa) (Fig. 6, hNHS lanes). Time
course experiments indicated that C4 and C3 binding to
FX517, like that of C1q, was rapid, with deposition occurring
as early as 1 min postincubation (data not shown). In these
studies we used well-characterized gonococcal strains that are
serum resistant (FA6564) and serum susceptible (F62) in order
to evaluate whether our methods could discriminate between
bacteria that bind low or high amounts of C4 and C3, respec-
tively (Fig. 6, left panel).
Terminal MAC binding. Western blots were also used to
detect the noncovalent binding of complement proteins C5b
through C8. In experiments measuring C6 and C7 binding to
H. ducreyi strains, more of each was deposited on FX517 than
on 35000HP (Fig. 7, right panel). Control experiments using
gonococcal strains revealed more C6 and C7 binding to F62
(serum sensitive) than to FA6564 (serum resistant) (Fig. 7, left
panel). In C9 binding experiments, more C9 was deposited on
serum-susceptible FX517 than on serum-resistant 35000HP
(15,000 cpm and 3,400 cpm, respectively) (Fig. 8). Taken to-
gether, these results show that more terminal membrane attack
complex (MAC) was deposited on serum-susceptible FX517
FIG. 5. C1q binding to H. ducreyi as measured by immunoblotting.
H. ducreyi strains were incubated with fNHS for the indicated time
periods. After binding of complement components, bacteria were pel-
leted and washed by cycles of centrifugation. Cell pellets with bound
complement components were subjected to SDS-PAGE and immuno-
blotting using polyclonal anti-human C1q. C1q is composed of three
individual chains, A, B, and C, that migrate at 27.5, 25.2 (doublet), and
23.8 kDa, respectively. Similar results were observed in three other
experiments. Normal human serum, 0.1 l, was loaded in the first lane
as a positive control (approximately 7 nanograms of C1q).
FIG. 6. Binding of C3 and C4 to H. ducreyi. Bacteria were incu-
bated in the absence of NHS or in the presence of hNHS or fNHS.
After washing bacteria to remove unbound serum proteins, bound C
proteins were detected by SDS-PAGE (reducing conditions) using
anti-human C3 and C4. NHS, 0.1 l, was loaded as a positive control.
The upper band in the NHS standard lane is the alpha chain, and the
lower band is the beta chain for both C4 and C3. FA6564 (serum
resistant) and F62 (serum susceptible) are gonococcal control strains.
Similar results were obtained in three other experiments.
FIG. 7. Binding of C6 and C7 by H. ducreyi. Bacteria were incu-
bated in the absence of NHS or in the presence of hNHS or fNHS.
After unbound proteins from bacteria were washed, bound proteins
were detected using anti-human C6 or C7 in Western blots. Similar
results were observed in three other experiments.
FIG. 8. Binding of terminal MAC complex. H. ducreyi strains were
incubated in fNHS or hNHS (10%) for 45 min at 35°C. Bacteria were
suctioned and washed with PBS, and an iodinated MAb directed
against a C5b-C9 neoepitope was added (1  106 cpm). After binding
of MAb and removal of unbound MAb by washing, bacterium-associ-
ated cpm were determined. Shown are the cpm bound in fNHS minus
the cpm bound in hNHS. The P value for 35000HP (35000) versus
FX517 was 0.0004.
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than on serum-resistant 35000HP, consistent with the previous
results from bactericidal assays.
Negative regulators of complement binding to H. ducreyi.
Some serum-resistant bacteria avoid killing by NHS by directly
binding negative regulators of complement (without a require-
ment for other functional complement components). Recently,
we demonstrated that H. ducreyi DsrA directly binds the neg-
ative complement regulator vitronectin (9). It has been pro-
posed that vitronectin may play a role in mediating resistance
in other bacteria (24, 36) by preventing the deposition of ter-
minal complement components (C5b through C9). If DsrA-
bound vitronectin was the sole factor and acted as a negative
complement regulator in H. ducreyi, the deposition levels of the
earlier complement components (antibody, C1q through C3)
would be expected to be similar for 35000HP and FX517, whereas
deposition of the terminal MAC components (C5b through C9)
would be greater on serum-susceptible FX517. This is not what
we observed in the experiments described above.
We also measured the binding of other negative regulators
of C to H. ducreyi to determine if this could account for its
serum resistance phenotype. fH is a cofactor for factor I (fI)-
mediated cleavage of the alternative pathway C3 convertase
(C3bBb). In addition to inhibiting alternative pathway activa-
tion, direct fH binding by bacteria also prevents the alternative
pathway amplification of an IgM-initiated complement cascade
(27). We used heated sera as a source of fH and C4bp (see
below), which are stable with heat treatment (27). hNHS was
mixed with H. ducreyi, and fH binding was measured in West-
ern blots using anti-fH. fH was minimally bound by H. ducreyi
strains 35000HP and FX517; both bound less than 50 ng of fH
per 107 CFU (data not shown). Similar results were seen when
purified fH was used in binding experiments (data not shown).
Previously, it was shown that stable serum resistance in
gonococcal Por1A strains, including FA6564, was due to the
binding of C4bp, a cofactor for fI (34). C4bp binding causes the
dissociation of the C3 convertase and also promotes the cleav-
age of C4b into the inactive fragments C4c and C4d. We
measured C4bp binding to bacteria using two methods. In the
first method, iodinated purified C4bp was mixed with bacteria,
and bound C4bp was measured by gamma counting of washed
bacteria. In experiments using iodinated C4bp and gonococcal
controls, the serum-resistant positive control strain, FA6564,
bound a mean of 578,759 	 49,121 cpm. The serum-susceptible
gonococcal negative control strain F62 bound 568 	 206 cpm
of C4bp. In H. ducreyi experimental samples, serum-resistant
H. ducreyi strain 35000HP bound a mean of 9,396 	 1,417 cpm,
and serum-susceptible H. ducreyi strain FX517 bound 3,567 	
34 cpm. In the second method of C4bp binding, hNHS was
used as the source of C4bp, and binding was detected by
Western blotting. In these experiments, slightly more C4bp was
associated with 35000HP than with FX517 (data not shown).
Both methods of C4bp binding revealed that between 10- and
60-fold more C4bp was associated with serum-resistant gonococ-
cal strain FA6564 than with serum-resistant H. ducreyi 35000HP;
thus, 35000HP bound relatively minor amounts of C4bp.
CRP is known to bind PC (40). Bacterium-bound CRP is
capable of directly activating the classical pathway of comple-
ment by binding C1q without a need for immunoglobulins.
Certain nontypeable H. influenzae strains express PC on their
LOS, which binds CRP present in NHS. These H. influenzae
strains are killed by the C cascade in an immunoglobulin-
independent manner. If H. ducreyi strain FX517 expressed PC,
it was possible that PC-mediated C1q binding, as opposed to
IgM, initiated the complement cascade. To examine this issue,
we removed CRP from serum and tested its ability to kill H.
ducreyi FX517 as well as the H. influenzae control strain 418,
which expresses PC. After CRP depletion, FX517 was killed in
a manner similar to that with CRP-replete serum (data not
shown); however, H. influenzae strain 418 was no longer killed.
Furthermore, using TEPC-15, a MAb that recognizes PC, no
reactivity was observed in Western blots of H. ducreyi LOS or
total cellular proteins. PC-positive LOS, but not PC-negative
LOS, from H. influenzae control strains was recognized by
TEPC-15 (data not shown). These data suggest that PC-medi-
ated CRP binding cannot account for the killing of FX517.
Depletion of IgM inhibits killing of FX517. In order to dem-
onstrate a cause and effect relationship between IgM binding and
killing of H. ducreyi strain FX517, we depleted immunoglobulin
(IgM or IgG) from human NHS. In these studies we chose to use
a reduced serum concentration (20%) for technical reasons. First,
20% serum approaches the lowest concentration of serum that
effectively kills FX517 (15). Leduc (22) recently showed that 10%
NHS results in about 69% survival, whereas 25% NHS kills 99%
or more (15). Furthermore, removing IgM (1 mg/ml) and IgG (10
mg/ml) from serum while maintaining intact complement is tech-
nically demanding, and we could conserve reagent sera by using
20% NHS instead of 50%.
Anti-human IgM agarose was briefly incubated with NHS on
ice to deplete the IgM and to preserve complement activity.
FX517 incubated in 20% fNHS, without the dilution effect of
agarose treatment, had a survival rate of 19% (Fig. 9). Mock
treatment of fNHS with agarose containing no ligand resulted
in 37% survival for FX517, presumably due to dilution effect
(
1/3 dilution). In contrast, treatment of serum with agarose
containing covalently bound anti-human IgM (IgM-depleted
serum) resulted in a 71% survival rate. The killing activity of
IgM-depleted NHS was restored when purified IgM was re-
constituted to normal serum concentrations (30% survival for
FX517). This level of survival is similar to the level obtained
for mock IgM-depleted sera, which are similarly diluted (37%).
Purified IgG added to IgM-depleted serum served as an addi-
tional control to ensure that the depletion of IgM from fNHS
did not adversely affect IgG levels or activity. The addition of
IgG, to a twofold excess of IgG, to IgM-depleted serum did not
restore killing (81% survival for FX517). The addition of heat-
inactivated serum (as a source of immunoglobulins) to IgM-de-
pleted serum restored killing activity, with FX517 exhibiting a
survival rate of 32%. In experiments not presented here, removal
of IgG from NHS using protein G agarose had no effect on the
killing of FX517. The above data suggest that IgM, but not IgG,
plays a critical role in NHS-mediated killing of FX517.
Absorption of NHS with FX517 removes bactericidal IgM.
To confirm IgM was responsible for initiation of the comple-
ment cascade, we incubated H. ducreyi strain FX517 dsrA with
NHS on ice to remove the antibodies responsible for killing
(putatively IgM) but maintain complement activity. FX517 sur-
vival in absorbed fNHS was 54% compared to only 1.9% for
unabsorbed fNHS (25% NHS without significant dilution)
(Fig. 10). Killing activity against FX517 dsrA was restored upon
addition of purified IgM or if heated NHS was added as a
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source of immunoglobulins, 4% and 5% survival, respectively.
The survival rate of FX517 in hNHS supplemented with IgM
was 90%, indicating that IgM-mediated killing required an
intact complement cascade. These data provide further evi-
dence that IgM is important in NHS-mediated killing.
DISCUSSION
Serum resistance. In order to initiate human infection, H.
ducreyi requires hemoglobin as a source of heme (3, 23). Dur-
ing acquisition of heme from blood, H. ducreyi is exposed to
human serum antibodies and complement. Thus, it is not too
surprising that H. ducreyi has evolved mechanisms to avoid com-
plement-mediated killing. The ability to avoid killing by NHS is an
important virulence factor of bacterial pathogens, including H.
ducreyi, since a dsrA mutant is highly attenuated (15).
Classical pathway is responsible for killing of FX517. In this
paper, we present four lines of evidence that the classical
pathway was responsible for killing of serum-susceptible strain
FX517 by fNHS. (i) EGTA, which inhibits the classical path-
way, inhibited killing. (ii) C1q, a C component unique to the
classical pathway, was required for killing, and more C1q was
bound by serum-susceptible FX517. (iii) Five- to 10-fold more
IgM was bound to FX517 than to the parent strain, 35000HP.
(iv) IgM was required for killing of FX517.
Prior to the discovery of the MBL pathway, Odumeru dem-
onstrated that EGTA/Mg (30) abolished the killing of serum-
susceptible H. ducreyi A77 (dsrA and los double mutant) and
concluded the classical pathway was responsible for killing.
EGTA/Mg also inhibits the MBL pathway; however, our evi-
dence suggests that the MBL pathway is not involved, since
MBL was not bound by H. ducreyi and C1q-depleted serum
failed to kill FX517. Thus, we have confirmed and extended
Odumeru’s early studies. Lagergard et al. studied serum resis-
tant H. ducreyi and found a minor role for the alternative
pathway in the killing of H. ducreyi (21). We did not conduct
specific experiments to assess the role of the alternative path-
way in the killing of FX517. However, our data from studies of
the classical and MBL pathways suggest that the alternative
pathway does not play a major role. Furthermore, it must be
noted that Lagergard’s and our studies are not comparable
because they used serum-resistant strains and NHS, immune
serum, and rabbit complement. Our studies used serum-sus-
ceptible H. ducreyi and NHS as a source of complement.
Antibody and complement deposition on H. ducreyi. More
IgM was deposited on FX517 than on 35000HP, and removal
of IgM prevented killing. Based on these data, we propose that
this event leads to complement activation on FX517. Two
possibilities may explain why more IgM was deposited on
FX517. Perhaps in the parent, DsrA physically shields another
surface component(s), possibly LOS, to which bactericidal IgM
antibodies are directed. Alternatively, perhaps a novel unde-
tected antigen containing a bactericidal epitope(s) is expressed
in the dsrA mutant compared to parent. Of the complement
components we measured, more complement (from C1q
through C9) was deposited on serum-susceptible strain FX517
than on serum-resistant strain 35000HP. For C4 and C3, the
kinetics of deposition was more rapid on FX517 than on
35000HP. Finally, perhaps the ability of the C cascade to be
deposited on 35000HP is prevented by DsrA.
The epitope for bactericidal IgM remains unknown. Natu-
rally occurring antibodies to LOS are found in NHS and are
often of the IgM isotype. For example, IgM anti-LOS antibod-
ies are responsible for the initiation of the classical C cascade
and subsequent killing of serum-susceptible gonococci (10). Se-
rum-susceptible gonococci grown in the presence of exogenously
supplied 5cytidinemonophospho-N-acetylneuraminic acid (CMP-
NANA) sialylate their LOS and are rendered serum resistant. Se-
rum-sensitive gonococci grown in media containing CMP-NANA
FIG. 9. Fresh normal human serum was treated as described here, and the bactericidal activity was determined using a 20% concentration. 1,
fNHS heated to 56°C to inactivate the complement (hNHS); 2, fNHS incubated on ice without treatment (fNHS); 3, fNHS incubated with agarose
containing no ligand on ice (mock IgM-depleted fNHS); 4, fNHS incubated with anti-human IgM agarose on ice (IgM-depleted fNHS); 5,
IgM-depleted fNHS reconstituted with IgM (IgM-depleted fNHS  IgM); 6, IgM-depleted fNHS reconstituted with IgG (IgM-depleted fNHS 
IgG); 7, IgM-depleted fNHS reconstituted with hNHS as a source of immunoglobulins (IgM-depleted fNHS  hNHS).
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sialylate their LOS and become serum resistant. H. ducreyi are able
to sialylate their LOS from endogenously synthesized CMP-NANA
pools. Nevertheless, H. ducreyi mutants unable to sialylate
their LOS remain fully serum resistant. Given the immuno-
chemical similarities of the LOS of gonococci and H. ducreyi,
these findings are somewhat surprising.
Yet another unusual phenomenon is that the highly trun-
cated H. ducreyi LOS mutants 35000HP glu (44) and gmhA (4)
are serum resistant (I. Nepluev and C. Elkins, unpublished
data). In many bacterial systems, LOS mutants are both serum
susceptible and avirulent. Human experimental chancroid
challenge experiments using 35000HP glu revealed that this
mutant retains virulence, consistent with the notion that serum
resistance is required for infectivity in humans (44). LOS mutants
have reportedly shown decreased attachment to keratinocytes (8),
yet apparently this had no significant effect on virulence. We think
it possible that LOS could be the target of the bactericidal IgM
antibodies described in this paper. Experiments are in progress to
identify the epitope(s) for bactericidal IgM.
We entertained the possibility that IgM was not involved in
the killing of FX517 and that an antibody-independent C1q-
dependent classical pathway mechanism was responsible. For
example, certain mutants of Klebsiella pneumoniae are killed as
a result of immunoglobulin-independent, direct C1q binding to
outer membrane porins and subsequent C activation (1, 2).
However, in our experiments, killing was abolished by IgM
depletion and restored by purified IgM addition, ruling out this
possibility. Another mechanism of antibody-independent clas-
sical pathway activation is mediated by PC (40). In H. influen-
zae, PC present on certain types of LOS binds CRP, leading to
C1q binding and subsequent killing (42). We were able to
exclude this possibility, since depletion of CRP had no effect
on the killing of FX517 and yet CRP-depleted sera no longer
killed PC-expressing H. influenzae. Furthermore, we were un-
able to demonstrate a PC epitope on H. ducreyi LOS. Other
mutants of gram-negative bacteria can activate the alternative
pathway, but it was inferred that this did not occur, since
inhibition of the classical/mannan binding protein pathway
(with EGTA/Mg) abolished killing of FX517.
Negative regulators of complement. In order to better un-
derstand the serum resistance observed in H. ducreyi, we stud-
ied the direct binding of negative regulators of complement to
H. ducreyi. Previously, we showed that vitronectin was bound
by H. ducreyi expressing dsrA, but in the present study we found
that vitronectin alone could not account for all of the observed
serum resistance. Vitronectin inhibits the membrane attack com-
plex, but differences in deposition of earlier complement compo-
nents between 35000HP and FX517 were observed, suggesting
vitronectin was not the sole mediator of serum resistance. In
looking for earlier negative regulators of complement, we
found about twofold more C4bp was bound by strain 35000HP
than by FX517. Gonococcal control strain 6564 bound up to
60-fold more than strain 35000HP. Binding of C4bp would
result in less C4 detected and later components on 35000HP
than by FX517. Although this is what we observed, we also
found that little C1q was bound by 35000HP prior to the step
C4bp affects. Less C1q binding is consistent with decreased
binding of IgM to 35000HP. Thus, the very modest C4bp bind-
ing cannot alone account for all of the differences in comple-
ment binding observed. It is possible that C4bp or vitronectin
bound to 35000HP contributes partially to serum resistance in
H. ducreyi 35000HP, but further studies are necessary. Surpris-
ingly, H. ducreyi strain 35000HP is also very resistant to killing
by a variety of specific surface-reactive antisera (19, 21). It is a
distinct possibility that such antibodies initiate the classical
pathway but that negative regulators of complement vitronec-
tin or C4bp inhibit subsequent complement-mediated killing.
Further studies are under way to determine if this occurs.
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